Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $9.6 million.

  • Avidity Biosciences' Accounts Payables fell 8060.37% to $9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 8060.37%. This contributed to the annual value of $8.5 million for FY2024, which is 7536.18% down from last year.
  • Avidity Biosciences' Accounts Payables amounted to $9.6 million in Q3 2025, which was down 8060.37% from $3.9 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Accounts Payables ranged from a high of $54.2 million in Q1 2025 and a low of $3.9 million during Q2 2025
  • Moreover, its 5-year median value for Accounts Payables was $26.4 million (2022), whereas its average is $25.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 14071.21% in 2022, then plummeted by 9043.59% in 2025.
  • Quarter analysis of 5 years shows Avidity Biosciences' Accounts Payables stood at $14.1 million in 2021, then skyrocketed by 131.25% to $32.6 million in 2022, then rose by 5.43% to $34.3 million in 2023, then crashed by 75.36% to $8.5 million in 2024, then rose by 13.77% to $9.6 million in 2025.
  • Its Accounts Payables stands at $9.6 million for Q3 2025, versus $3.9 million for Q2 2025 and $54.2 million for Q1 2025.